NCT06835179: SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
- State
- Not started
- Phase
- Phase 2
- People
- 28 planned
- Started
- Feb 2025
- Primary completion
- Feb 2027
- Arms
- Experimental group
- Results
- None posted
- 19 Feb 2025: Trial registered